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a b s t r a c t
Peroxisome biogenesis disorders (PBD) are autosomal recessive disorders in humans characterized by
skeletal, eye and brain abnormalities. Despite the fact that neurological deﬁcits, including peripheral
nervous system (PNS) defects, can be observed at birth in some PBD patients including those with PEX10
mutations, the embryological basis of the PNS defects is unclear. Using a forward genetic screen, we
identiﬁed a mouse model for Pex10 deﬁciency that exhibits neurological abnormalities during fetal
development. Homozygous Pex10mutant mouse embryos display biochemical abnormalities related to a
PBD deﬁciency. During late embryogenesis, Pex10 homozygous mutant mice experience progressive loss
of movement and at birth they become cyanotic and die shortly thereafter. Homozygous Pex10 mutant
fetuses display decreased integrity of axons and synapses, over-extension of axons in the diaphragm and
decreased Schwann cell numbers. Our neuropathological, molecular and electrophysiological studies
provide new insights into the embryological basis of the PNS deﬁcits in a PBD model. Our ﬁndings
identify PEX10 function, and likely other PEX proteins, as an essential component of the spinal locomotor
circuit.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Clinically, peroxisome biogenesis disorders (PBD) are lethal
congenital diseases with a spectrum of severity and progressive-
ness (Braverman et al., 2013; Steinberg et al., 2006). Infants born
with Zellweger syndrome (ZS), the most severe disease within the
spectrum of PBD, may show a lack of muscle tone and an inability
to move, indicating an embryonic origin of the disorder (Wanders
and Waterham, 2005, 2006). ZS is lethal within six months and is
associated with impaired neuronal migration, abnormal brain
development and severe degradation of the white matter. Patients
with the PBD, neonatal adrenoleukodystrophy (NALD), display
demyelination of white matter tracks in the brain and spinal cord,
which results in progressive weakness and mortality within ten
years (Steinberg et al., 2006). Ataxia, demyelination and loss of
axon integrity are common in patients with peroxisomal dysfunc-
tion (Baes and Aubourg, 2009; Steinberg et al., 2006). A common
cellular pathology of these diseases is the inability to generate
functional peroxisomes to meet the metabolic demands of the cell.
Peroxisomes are single-membrane bound subcellular orga-
nelles present in all eukaryotic cells. Mammalian peroxisomes
are involved in the breakdown of very long chain fatty acids
(VLCFA), amino acids, and polyamines, decomposition of hydrogen
peroxide, as well as the biosynthesis of plasmalogens, which are
abundant in myelin, bile acids, and polyunsaturated fatty acids.
Peroxisome enzyme content, number, and metabolic functions are
determined by the cell type and species (Brown et al., 2008).
Peroxisomal proteins called peroxins (PEX) control peroxisome
assembly, ﬁssion, and shuttling of fully folded protein cargo
across peroxisomal membranes (Lanyon-Hogg et al., 2010; Van
Veldhoven and Baes, 2013; Wanders, 2014). Thus, disruptions in
PEX proteins could alter biosynthesis and/or degradation of target
substrates leading to PBD in humans.
The zinc RING-ﬁnger peroxin, PEX10, is necessary for peroxi-
some assembly, for import of target substrates, and for recycling or
degradation of protein complexes and amino acids (Oeljeklaus
et al., 2012; Williams et al., 2008, 2012). For example, PEX10 binds
to PEX5 and helps dock PEX5 at the pore to allow cargo import.
Moreover, PEX10 and the conserved RING domain peroxisomal
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integral membrane proteins PEX2 and PEX12 act as E3-ubiquitin
ligases (Platta et al., 2009; Williams et al., 2012). The RING
peroxins serve to mono- or poly-ubiquitinate PEX5 to control
PEX5 receptor recycling or degradation. Poly-ubiquitinated PEX5
is sent to the proteasome for degradation whereas mono-
ubiquitination of the PEX5 receptor allows it to return to the
cytosol where it can bind new protein cargo for import into the
peroxisomes (Agne et al., 2003; Chang et al., 1999b; Thoms and
Erdmann, 2006).
Mice lacking neural Pex5 develop postnatal neurological defects
with motor dysfunction due to defects in axon integrity, demye-
lination and neuroinﬂammatory reactions (Bottelbergs et al., 2012;
Hulshagen et al., 2008; Krysko et al., 2007), suggesting a neural
basis to the etiology of PBD in patients with mutations in PEX5.
Neurological defects such as cerebellar ataxia, spinal ataxia,
progressive ataxia and reduced cognitive capacity are diagnoses
in patients with mutations in the PEX10 gene (Steinberg et al.,
2004; Warren et al., 2000). However, no published vertebrate
model exists with a mutation in Pex10. Thus, it is unclear how the
loss of vertebrate PEX10 contributes to PBD disease pathology.
Here, we identify a mouse model with a mutation in Pex10 that
causes neonatal mortality and defects in embryonic locomotion.
Furthermore, we characterize the biochemical defects and pathol-
ogy of Pex10 mutant mice. Pex10 homozygous mutants display
prenatal pathology including defects in axonal integrity, decreased
Schwann cell number and defects at the neuromuscular interface.
Therefore, this Pex10 model provides new insight into the embry-
ological origin of PBD pathology and highlights the role of per-
oxisomes in embryonic peripheral nervous system development.
Material and methods
Forward genetic screen and identiﬁcation of the Pex10 mutation
ENU mutagenesis was performed as described (Kasarskis et al.,
1998) on males of C57BL/6J background and then outcrossed onto
129S1/Svlmj background to score G3 embryos at embryonic day
18.5 for recessive mutations that affect embryonic locomotion.
Through meiotic mapping which followed linkage between the
non-motile phenotype and C57BL/6J markers, the genetic region
containing the mutation that affected locomotion was ﬁrst
mapped to the proximal third of chromosome 4 using a panel of
96 MIT and SKI SSLP markers and then narrowed to a 7 Mb region
by the use of additional MIT SSLP markers on the telomeric end of
chromosome 4. DNA from phenotypic mutant embryos (n¼4) was
sent to the Broad Institute to identify all C57BL/6J regions, which
conﬁrmed localization to a 3 Mb interval of the telomeric region of
chromosome 4. DNA from phenotypic embryos was sent for whole
exome enrichment followed by next generation sequencing (Oto-
genetics, Inc) and this identiﬁed only 1 candidate homozygous
variant in the Pex10 gene within the surrounding 20 Mb region of
chromosome 4. This variant was a single base substitution (G to A)
that introduces a C294Y non-synonymous amino acid change.
Using Ensembl Genome Browser (ensembl.org) combined with
whole exome capture data analysis, PEX genes and genes involved
in peroxisome function (ABC transporter family and PPAR family)
were subsequently examined yet no homozygous variants in exon
sequences were found, other than the Pex10 mutation. To conﬁrm
the mutation in Pex10, genomic DNA in overlapping segments of
the Pex10 gene was ampliﬁed by PCR from phenotypic E18.5
embryos and compared with control E18.5C57Bl/6J DNA. Subse-
quently, embryos were genotyped as follows: Tissue was placed in
tail lysis buffer (100 mM TrisCl pH8.0, 5 mM EDTA, 0.2% SDS,
200 mM NaCl) overnight. DNA was ampliﬁed using Taqman Gold
(Applied Biosystems) with primer set to Pex10 (forward primer:
AGAACCCTCATCCATTTGCCTGGT; reverse primer: AAAGTACCT-
CAAGCTCCCTGCACA. PCR ampliﬁcation was performed for 35
cycles at 55 1C. PCR product was sent to Barbara Davis Center
Molecular Biology Service Center at the University of Colorado
Denver for sequencing. The ofﬁcial nomenclature of this mutant
allele is Pex10m1Nisw, but for simplicity we will use Pex10CY
throughout the manuscript. All of the data presented here were
obtained after outcrossing 412 generations onto 129S1/Svlmj
background.
Mouse embryonic touch assay
This touch assay was designed to examine the spinal locomotor
response from the activation of the muscle spindles that carry
signals to the dorsal root ganglion, to the interneuron relays
between the dorsal root ganglion and motoneurons, and the
motoneuron activation of the muscle to induce a contraction.
Embryos were dissected from timed pregnant dams and placed in
room temperature oxygenated mouse Tyrode’s solution. To induce
limb movement, the foot-pads were pinched with tweezers. For
example in E18.5 wildtype embryos, pinching induces paw retrac-
tion and cross-extensor reﬂexes. Both forelimb and hindlimb were
assayed and retraction of the limb was scored as 1, no retraction of
limb was scored as 0 and slow or modest retraction of limb was
scored as 0.5. We also scored for S-shaped movements in axial
muscles by touching the forceps to the dorsal rib cage. Touch assay
was performed on each litter to identify phenotypic embryos. The
genotype of all embryos was conﬁrmed as above.
Biochemical analysis
Bloodspots were collected from E18.5 embryos and from adult
mice (42 months old) on ﬁlter paper (Whatman 903, GE Life-
sciences). Markers of PBD were analyzed by the Peroxisomal
Diseases Laboratory within the Moser Center for Leukodystrophies
at the Kennedy Krieger Institute (Baltimore, MD). Human samples
from normal control and individuals with PBD and rhizomelic
chondrodysplasia punctacta (RCDP) were collected and analyzed
by the Kennedy Krieger Institute and only the data without
identifying information was provided. Lyso-phosphatidylcholines,
(lyso-PCs), including C26:0 lyso-PC, peroxisomal bile acid inter-
mediates and plasmalogens were analyzed by combined liquid
chromatography–tandem mass spectrometric (LC–MS/MS) method
(Hubbard et al., 2009, 2006; Johnson et al., 2001; Zemski Berry and
Murphy, 2004).
Cell culture
Mouse embryonic ﬁbroblasts (MEFs) were isolated from E18.5
limb dermis. Dermis was removed from limbs and cut into small
fragments and dissociated in 0.25% trypsin-EDTA (Gibco) for
15 min at 37 1C. Fragments were sheared by 5 passes through a
1000 μl pipette in DMEM/F12 (Gibco) with10% FCS (Gibco).
Suspension was centrifuged and re-suspended in DMEM/F12
medium consisting of 10% FCS, penicillin/streptavidin (Gibco)
and L-glutamine (Gibco). Cells were re-plated at least once before
experimentation.
Peroxisomal localization
For peroxisomal localization studies, a ‘LQSKL’ PTS1 signal
sequence from acyl-CoA oxidase was appended to the C-
terminus of an EGFP reporter construct (in pCDNA3.1) using PCR.
MEFs from wild-type or homozygous mutant Pex10CY embryos
were plated on 18-mm glass coverslips in DMEM/F12 (Gibco) with
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10% FBS, and transiently transfected with the EGFP-SKL reporter
using MEF 2 Nucleofector Kit (Lonza) according to the manufac-
turer’s protocol. 24 h after transfection, cells were ﬁxed using 4%
paraformaldehyde and imaged on an Olympus IX71 microscope
equipped with a spinning disc scan head (Yokogawa Corporation
of America) with a 60x/NA 1.4 objective. 488-nm excitation
illumination was delivered from an AOTF controlled laser launch
(Andor Technology) and images collected on a 10241024 pixel
EM-CCD camera (iXon; Andor Technology).
Docosahexaenoic acid study
Docosahexaenoic acid (DHA) was obtained from Cayman Che-
mical Company (Michigan, USA). After detection of a vaginal plug,
Pex10 heterozygous females received drinking water supplemen-
ted with 50 mM of DHA, throughout the entire gestation. The DHA
concentration used was determined according to Correia et al.
(2012), which showed gestational affects of DHA on gastric
mucosa colonization.
Electron microscopy
Sciatic nerves from E18.5 embryos were dissected and ﬁxed
with 2% paraformaldehyde/2.0% glutaraldehyde in phosphate
buffer (pH 7.2) for 1 h at room temperature. Nerves were trans-
ferred to 2.0% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2)
overnight at 4 1C. The sciatic nerve was dissected into segments,
followed by a secondary post-ﬁxation in 2% osmium tetroxide and
1.5% potassium ferrocyanide in phosphate buffer for 1 h at room
temperature. Samples were dehydrated through sequential etha-
nol rinses (50, 70, 90, 95 and 100% ETOH) and embedded in Epon/
Araldite resin and polymerized overnight at 60 1C. Ultrathin
sections were cut, placed on copper mesh grids and double
contrasted with 2% aqueous uranyl acetate and Reynold’s lead
citrate. Due to artifacts present at the peripheral regions of the
cross sections, only the central region of the sciatic nerve was
examined. Grids were photographed using a FEI Technai G2
BioTwin transmission electron microscope.
Immunohistochemistry
Wildtype and mutant MEFs were ﬁxed in 4% paraformaldehyde
for 10 min then permeabilized with 0.1% Triton/PBS for 30 min.
Non-speciﬁc binding was blocked with 2% fetal bovine albumin
(Sigma) for 30 min. Primary antibody to catalase at 1:500 (Sigma)
was added for 1 h at room temperature. Secondary antibody
(Alexa Fluor 488, 1:800, Molecular Probes) was applied for 1 h
before washing and mounting.
Embryos were dissected and pinned to a Sylgard-coated dish in
4% paraformaldehyde for 1 h. Embryos were placed in 5% sucrose
for 1 h at room temperature before transfer into 30% sucrose
overnight at 4 1C followed by embedding in OCT. Frozen sections at
10 μm thickness through the spinal column were collected and
ﬁxed in 1% paraformaldehyde for 10 min. Conditions for immuno-
labeling are described below. TUNEL labeling was according to
manufactures instructions (Millipore). After TUNEL labeling,
Hoechst 33342 (Life Technologies) was added for 15 min at room
temperature.
Muscles were dissected and pinned to a Sylgard-coated dish in 4%
paraformaldehyde for 10 min then permeabilized with 0.2% Triton/PBS
for 30 min. α-BTX conjugated Alexa 555 and Alexa 647 (1:500, Life
Technologies) were used for labeling of acetylcholine receptors
(AChRs) at the membrane. Non-speciﬁc reactivity was blocked with
2% BSA/PBS for 1 h. Primary antibodies for β-tubulin III (1:1000,
Covance), S100B (1:1000, Sigma; S2644 used for E18.5 sciatic;
HPA015768 used for E15.5 sciatic) neuroﬁlament-M (1:100; Sigma)
and synaptophysin (SV2, 1:200; DSHB) were applied overnight at 4 1C.
Secondary antibodies (Alexa Fluor 488 and Alexa Fluor 568-
conjugated to speciﬁc primary, 1:800, Molecular Probes) were applied
for 1 h.
Confocal microscopy
Immunolabeled samples were examined on a Zeiss LSM 510
confocal laser scanning microscope. Emitted ﬂuorescence was direc-
ted to a photomultiplier with long-pass ﬁlter. Confocal ﬂuorescence
intensity data were recorded as the average of four line scans per
pixel and digitized at 8-bit, with photomultiplier gain adjusted such
that maximum pixel intensities were o70% saturated.
Sharp electrode recordings
Current-clamp sharp electrode recordings were performed as
described (Plomp et al., 1992). E18.5 diaphragms were dissected
and kept at room temperature in mouse Normal Ringers. Dia-
phragm muscle ﬁbers were impaled with glass capillary micro-
electrode (30 MΩ resistance) made using a P-97 microelectrode
puller (Sutter Instruments) and ﬁlled with 3 M KCl (Brown et al.,
2008). Evoked responses were elicited by a 0.2-ms maximal
stimulus applied to the phrenic nerve using a suction electrode
and pulse generator (STG 1002, ALA Scientiﬁc Instruments).
Evoked and miniature endplate potentials (MEPP) were recorded
using an Axoclamp-2A ampliﬁer (Axon Instruments) and DigiData
1322A (Molecular Devices). Muscle ﬁber membrane potentials
were adjusted to Em¼70 mV under current clamp. Data was
extracted and analyzed with Axoscope 10 software (Molecular
Devices).
Quantiﬁcation
In wildtype spinal cord cross sections, white matter is clearly
delineated by rostral and caudal axon tracks and revealed using
antibodies to Medium Neuroﬁlament (NF-M: NF-160) and β-
tubulin III (β-TubIII). The white matter tracks were captured as a
region of interest (ROI) by Zen 2009 software (Ziess). The inten-
sities of β-TubIII and NF-M were quantiﬁed within the ROI. A ratio
of NF-M intensity to the β-TubIII intensity was produced for each
white matter region. This data was normalized to control white
matter NF-M: β-TubIII intensity. The level of β-TubIII brightness
was equally decreased in Fig. 2G–K to visualize NF-M labeling.
The soleus muscle and ventral quadrant of the diaphragm are
easily identiﬁed by the stereotypical pattern of innervation and
AChR cluster placement. These muscles in wildtype embryos show
a high degree of reproducibility in axon branching, endplate
number and distribution. In diaphragms, endplate region was
quantiﬁed by drawing a line between the most distal α-BTX
positive endplates every 0.2 mm on each side of the centralized
phrenic nerve in the ventral diaphragm quadrant in comparison to
the total width of the diaphragm. Percentage of AChR clusters was
performed on compressed z-stack images. Endplate number was
quantiﬁed on z-stack images of entire muscle by dividing the
ventral quadrant into 0.1 mm bins from central branch in ventral
quadrant. The Zen 2009 software then calculated the size of the
endplates.
Statistical analysis
The unpaired two-tailed Student’s t test was used to compare
means for statistical differences. Unless otherwise mentioned
n45 for all experiments. Data in the manuscript are represented
as mean7SEM unless otherwise indicated. Po0.05 was consid-
ered signiﬁcant.
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Study approval
All experiments were conducted in accordance with the pro-
tocols described in the Guide for the Care and Use of Laboratory
Animals (NIH. Revised 2011).
Results
Forward genetic screen for locomotor defects identiﬁes a mutation in
Pex10
Through a chemically induced mutagenesis screen in mice, we
identiﬁed a recessive mutation in which homozygous mutant
embryos display a progressive loss of limb movement from
embryonic day 17.5 (E17.5) to birth (Fig. 1A). At birth, these mice
show an inability to breath, turn blue, and die shortly thereafter
(Fig. 1B). Meiotic mapping, whole exome enrichment, and next
generation sequencing (NGS) identiﬁed a homozygous point
mutation in the peroxisomal biogenesis factor 10 (Pex10) gene
on chromosome 4 in embryos with locomotor deﬁcits (184/184
reads). This single G to A nucleotide change creates a C294Y non-
synonymous amino acid change (Fig. 1C) that would be expected
to disrupt the crucial second zinc RING ﬁnger binding domain
(C3HC4) important for E3 ligase activity in PEX10. This corresponds
to amino acid 316 in human PEX10. The mutant line is called
Pex10m1Nisw and for simplicity we refer to it here as Pex10CY. No
other peroxisomal factor showed a homozygous or heterozygous
Fig. 1. Identiﬁcation of Pex10CY/CY mutants with defects in peroxisome function. (A) Touch assay to examine movement during late stages of embryonic mouse development
shows a progressive loss of locomotor movement in Pex10CY/CY mutants. (B) Neonatal littermates within 2 h of birth. Pex10CY/CY mice are cyanotic and show no milk in the
stomach (black arrows). (C) A cysteine in the conserved PEX10 zinc ring ﬁnger binding domain (red letters, C3HC4) is mutated in Pex10CY/CY mice (asterisk). (D) Surviving
Pex10CY/CY mouse (right) shown with wildtype littermate. (E). Difference in weight between Pex10CY/CY mice (n¼2) and wildtype littermates (n¼3). (F) and (G) Antibodies to
catalase label the peroxisomes in wildtype embryonic ﬁbroblast (F) but shows only diffuse cytoplasmic labeling in Pex10CY/CY MEFs (G). (H) and (I) Peroxisomal import signal
EGFP-SKL is localized to peroxisomes in wildtype MEFs (H) but no punctate labeling is seen in Pex10CY/CY MEFs (I). Scale bar¼50 μm.
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variant by whole exome enrichment and NGS. While mutations at
amino acid 316 in humans have yet to be discovered, mutations at
310 and 314 are associated with NALD and Zellweger syndrome
(Krause et al., 2006; Warren et al., 1998). The great majority of
Pex10CY/CY mice die within the ﬁrst few hours of birth although
two survived (o2%; 2 of 132 conﬁrmed homozygous mutations).
These survivors showed a severe decrease in size and weight
(Fig. 1D and E) and an ataxic gait. Ataxia is also observed in
humans with PEX10 mutations.
Testing for peroxisomal biogenesis disorders often involves
harvesting and examination of human ﬁbroblasts for peroxisomal
markers such as the enzyme catalase. Patients with PEX10 muta-
tions have cytosolic catalase staining but lack catalase staining in
peroxisomes (Chang et al., 1999a, 1999b). In ﬁbroblasts from
wildtype mice, catalase staining shows a punctuate pattern of
immunoﬂuorescence typical of peroxisomes (Fig. 1F). In contrast,
ﬁbroblasts derived from E18.5 Pex10CY/CY embryos show only
diffuse staining in the cytoplasm (Fig. 1G). To examine peroxisomal
targeting, EGFP fused to a PTS1 peroxisomal targeting signal ‘SKL’
(EGFP-SKL) was transfected into ﬁbroblasts. In wildtype ﬁbro-
blasts, EGFP-SKL was expressed in a punctuate expression pattern
typical of peroxisomes (Fig. 1H). However, in ﬁbroblasts derived
from Pex10CY/CY embryos, EGFP-SKL was expressed in a diffuse
pattern, suggesting that Pex10CY/CY ﬁbroblasts lack peroxisomal
import of EGFP-SKL (Fig. 1I). These results indicate the PTS1
peroxisomal targeting signal pathway for import of peroxisomal
matrix proteins is disrupted in the mutant ﬁbroblasts. Taken
together, our genetic screen identiﬁed a mouse Pex10 model that
can be used to study the embryological basis of PBD neurological
deﬁcits.
Biochemical abnormalities in Pex10CY/CY mice
Despite the evidence that PBD phenotypes can be observed at
birth in human patients (Steinberg et al., 2006; Wanders and
Waterham, 2005, 2006) and in our mouse model, it appears that
biomarkers of peroxisomal function have not been examined
during late embryonic development. Thus, we evaluated PBD
markers at E18.5, when the locomotor defect was apparent. Blood
samples were collected from E18.5 embryos, adult control mice,
the heterozygous (Pex10CY/þ) birthing females and the two
Pex10CY/CY adults to assay for erythrocyte plasmalogens, VLCFA,
and bile intermediates for comparison to patient samples of PBD
and ZS. In the Pex10CY/CY embryos, plasma VLCFA levels were 10-
fold higher (C26:0-LPC%; n¼8) compared to wildtype littermates
(n¼10; Table 1). Conversely, total plasmalogen levels were 21-
fold lower in Pex10CY/CY embryos relative to wildtype littermates
(Table 1). Thus, VLCFA was elevated and plasmalogen levels
decreased in Pex10CY/CY embryos, in a similar trend as that seen
in human PBD patients. Subtle variations in plasmalogens were
detected in Pex10CY/CY adult mice that survived birth, which is
intriguing but we could not determine signiﬁcance as only two
animals survived over the course of these studies. Peroxisomal bile
acid intermediates as measured by 3,7-dihydroxy-5-colest-26-oic
acid (DHCA) and 3,7,12-trihydroxy-5-cholestan-26-oic acid (THCA)
were 11 fold and 28 fold increased in Pex10CY/CY embryos
compared to wildtype littermates (Table 1); however, the levels
were not in the range found in patients with PBD or rhizomelic
chondrodysplasia punctata (RCDP), which is a non-leathal disease
due to a mutation in PEX7(Table 1). This difference may be due to
differences between mouse and human, between fetal and post-
natal development, or the Pex10 mutation. Nevertheless, our data
provide evidence that peroxisomal function and spinal locomotor
function are severely disrupted in Pex10CY/CY mutant embryos, and
that the Pex10 mutant model reﬂects a number of peroxisomal
biochemical hallmarks identiﬁed in human PBD patients.
PEX10 is a major component of the peroxisome needed for both
biosynthesis and degradation of proteins and fatty acids. We
attempted to decrease the embryonic mortality by providing a
diet of docosahexaenoic acid (DHA) to pregnant dams from vaginal
plug to birth. However, homozygous neonates were cyanotic and
died shortly after birth at a normal Mendelian ratio (17:36:15).
At weaning ages, we did not observe an increase in Pex10CY/CY
survivors.
Spinal cords of Pex10CY/CY embryos show no apoptosis defect
Plasmalogens, which are synthesized in peroxisomes and
which are deﬁcient in PBDs, are critical for neural (neurons and
glial) cell survival and plasmalogens are a signiﬁcant component of
the glial myelin sheath. To determine whether locomotion defects
were a consequence of apoptosis of neurons and glia that control
limb movement, we performed TUNEL labeling. We examined
E18.5 cervical and lumbar enlargements where the fore- and
hindlimb motoneurons are located from Pex10CY/CY embryos with
immobile hindlimbs but mobile forelimbs compared to wildtype
littermates. No signiﬁcant differences were detected in the num-
ber of apoptotic cells at cervical or lumbar levels or in the sensory
neurons within the dorsal root ganglion (DRG) (Fig. 2A–F; actual
cell counts presented in legend to Fig. 2). This data suggests that
apoptosis does not underscore the locomotive defects in Pex10CY/CY
embryos.
The hallmark of severe peroxisomal biogenesis disorders is
demyelinated white matter tracks in the central nervous system.
Table 1
Biochemical analysis of human and mouse bloodspots.
Mice Mice Human samples
E18.5 E18.5 E18.5 Adult Adult Adult
Pex10þ /þ Pex10CY/þ Pex10CY/CY Pex10þ /þ Pex10CY/þ Pex10CY/CY Normal PBD RCDP
n¼10 n¼4 n¼8 n¼6 n¼6 n¼2 n¼190 n¼62 n¼9
Total PE plasmalogen 13.33 79.7 4.4170.38n 0.6170.11n 7.1971.06 16.4879.21 6.0575.15 64.18740.30 26.66730.28 10.72712.07
C26:0-LPC% 0.3070.15 0.4770.06 3.60 71.75n 0.2970.08 0.1670.02 0.1770.09 0.2170.10 6.0473.47 0.5270.04
DHCA 0.0570.04 0.0470.03 0.6170.18n 0.0270.02 0.1070.03 0.1670.00 0.0270.02 24.06729.95 1.1473.13
THCA 0.0170.01 0.3870.21n 0.3970.06n 0.0370.02 0.5270.13n 1.0370.09 0.0370.02 13.12724.96 0.3571.10
Average value from bloodspots (see Material and methods section), Surviving adult Pex10CY/CY shows calculated median. Heterozygous adults were birthing females that
produced phenotypic neonatal mice. PBD are patients with Peroxisomal Biogenesis Disorder. RCDP are patients with rhizomelic chondrodysplasia punctacta (due to mutation
in PEX7). Abbreviations: PE¼ethanolamine phospholipids, DHCA¼dehydrocholic acid, THCA¼3 alpha, 7 alpha, 12 alpha-trihydroxy-5 beta-cholestan-26-oic acid,
LPC¼ lysophosphocholines. Asterisks indicates signiﬁcance by t-test po0.005 while values are 7SD.
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Decreased peroxisomal function in oligodendrocytes leads to the
accumulation of VLCFA which is damaging for the nervous system
(Baes and Aubourg, 2009; Kassmann et al., 2007). VLCFA induce
oxidative stress and decreased peroxisomal function in oligoden-
drocytes (Baarine et al., 2012). Therefore, we examined the axons
in the white matter regions at lumbar and cervical enlargement
levels of the spinal cord of E18.5 Pex10CY/CY embryos and littermate
controls. Medium Neuroﬁlament (NF-M) labeling was utilized
to identify ﬁber track defects in axon integrity, while β-tubulin
III labeling was utilized for baseline labeling of all neurons. Spinal
cord cross sections at the level of the cervical enlargement showed
no signiﬁcant difference between Pex10CY/CY and littermate controls
Fig. 2. Pex10CY/CY spinal cords show defects in white matter axons. (A)–(F) TUNEL labeling to detect apoptotic cells (green) in E18.5 wildtype (A) and (D) and Pex10CY/CY
(B) and (E) spinal cord enlargements (the regions of the spinal cord that harbor limb innervating motoneurons) at cervical (A) and (B) and lumbar (D) and (E) levels (blue are
nuclei stained with Hoechst 33342, white arrows identify TUNEL labeled cells). (C) and (F) Quantiﬁcation of TUNEL labeling/total nuclei shows no statistical difference in
apoptosis between wildtype and Pex10CY/CY spinal cords or sensory neurons within the dorsal root ganglion (DRG), (n¼16 sections from 3 embryos, average cells per slice
ranged from 2996 to 4552; Cervical level in wild type: 1.9670.08%, Pex10CY/CY: 2.1670.10%; p¼0.39; Lumbar wild type: 1.0470.17%; Pex10CY/CY: 1.8170.11%; p¼0.28; DRG
cervical wildtype 0.3670.15%; Pex10CY/CY 0.2770.11%; p¼0.4; DRG lumbar wildtype 0.0970.08%; Pex10CY/CY 0.1170.05%; p¼0.32). (G)–(L) Neuroﬁlament (NF-M, red) and
β-tubulin III (β-TubIII, green) label axons in spinal cord enlargements at cervical (G) and (H) and lumbar (J) and (K) levels (brightness level of β-TubIII was equally lowered on
(G), (H), (J), (K) to allow visualization of NF-M; insets show NF-M alone). (I) and (L) Quantiﬁcation of the ratio NF-M:β-TubIII intensity normalized to wildtype in white mater
region of spinal cords (white matter region is to the right and below the yellow dashed line). Scale bar¼200 μm. Asterisk in L indicates a signiﬁcant difference (p¼0.004;
t-test).
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(Fig. 2G–I; intensity of NF-M/β-tubulin III normalized to control was
0.9270.08 in Pex10CY/CY, 3 embryos; p40.05). However, at the
lumbar level, Pex10CY/CY embryos that were hindlimb immobile
showed a signiﬁcant decrease in NF-M labeling compared to
littermate controls (Fig. 2J–L, 0.3170.12 in Pex10CY/CY, 3 embryos;
p¼0.004). This data points to defects in axon integrity in white
matter tracks of Pex10CY/CY embryos and this may in part underscore
the hindlimb immobility defect.
Progressive developmental defect in Pex10CY/CY axon integrity
Motoneuron axons enter white matter tracks within the spinal
cord prior to exit into the periphery to innervate muscle in a
stereotypical pattern (Hanson and Landmesser, 2003). Demyelina-
tion and degeneration of the central nervous system in patients
with PBD has been the focus of previous studies. In an animal
model of Pex7 mutation leading to non-lethal RCDP, defects in
Fig. 3. Pex10CY/CY sciatic nerves display Schwann cell and axon integrity defects. (A) and (B) Isolated E18.5 wildtype and Pex10CY/CY sciatic nerves imaged by electron
microscopy. (A) Central region of sciatic nerve showing stereotypical encapsulation of axons bundles by early Schwann cells. (B) Similar region in Pex10CY/CY sciatic nerves
shows defects in encapsulation of axons bundles and early Schwann cells are either absent or show abnormal morphology as elongated ﬁbroblast-like cells. (C)–(R) Labeling
with antibodies to NF-M (axons, red), S100B (Schwann cells, green) and Hoechst 33342 (nuclei, blue) of E18.5 (C)–(J) and E15.5 (K)–(R) wildtype and Pex10CY/CY sciatic nerves.
(C)–(F) E18.5 wildtype sciatic nerves show axon and Schwann cell labeling throughout the cross section. (G)–(J) E18.5 Pex10CY/CY sciatic nerves have reduced labeling of axons
and Schwann cells in the central region of sciatic nerve. (K)–(R) E15.5 wildtype and Pex10CY/CY sciatic nerves from hindlimb cross sections have similar distribution of axon
and Schwann cell labeling. (A) and (B) Scale bar¼5 μm. (C)–(R) Scale bar¼50 μm.
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myelination and remyelination within the peripheral nervous
system were detected in postnatal and adult animals (da Silva
et al., 2014). Here we asked whether a PNS abnormality might
have an embryological origin, which could lead to progressive
embryonic locomotor defects. Schwann cells are the principal glia
cells that myelinate the PNS. At E18.5, Schwann cells encapsulate
multiple motor axons (Jessen and Mirsky, 2005) and muscle
innervation by the sciatic nerve is completed. Utilizing electron
microscopy (EM) at E18.5, cross sections of dissected sciatic nerves
from hindlimbs of wildtype embryos showed Schwann cells
encapsulating axon bundles within the central region of the sciatic
(Fig. 3A). In contrast, Pex10CY/CY sciatic axons lacked conventional
bundling, there was no evidence of Schwann cells with normal
morphology near axons and, instead, ﬂattened ﬁbroblast-like cells
were present (Fig. 3B). This data suggests defective axon bundling
by Schwann cells and axonal defects in embryonic Pex10CY/CY
sciatic nerves.
To explore further the defect in axon-Schwann cell interaction
in Pex10CY/CY sciatic nerves, cross sections of E18.5 sciatic nerves
were labeled with antibodies to NF-M to label axons, S100B to
label Schwann cells and Hoechst to label nuclei. Littermate control
sciatic nerve cross sections showed S100B positive Schwann cells,
and NF-M positive axons throughout the section (Fig. 3C–F). In
contrast, cross sections of Pex10CY/CY sciatic nerves showed S100B
and NF-M positive cells around the perimeter but these markers
were greatly reduced in intensity within the central regions of the
nerve, although nuclei were present (Fig. 3G–J). The E18.5 anti-
body labeling and EM data suggest defects in axonal integrity,
perhaps due to defective Schwann cell function. We then exam-
ined axon and Schwann cell labeling of the sciatic nerves at an
earlier time point, E15.5. This showed that E15.5 wildtype and
Pex10CY/CY embryos had similar levels of NF-M and S100B reactivity
(Fig. 3K–R). The normal labeling at E15.5 but disrupted labeling at
E18.5, combined with the EM data, is consistent with the normal
movement of Pex10CY/CY embryos at early fetal stages but progres-
sive loss of movement at later fetal stages. Together these data
suggest that the progressive loss of hindlimb movement corre-
sponds to a progressive developmental defect in axon integrity of
Pex10CY/CY sciatic nerves.
Synaptic machinery defects in Pex10CY/CY hindlimb muscle
The defects in axon integrity in Pex10CY/CY sciatic nerves might
suggest deterioration of neuromuscular synapses in hindlimb
muscles. Axons extend within muscles to form neuromuscular
synapses or junctions (NMJ). Acetylcholine (ACh) is transmitted by
action potential induced vesicular release onto ACh receptors
(AChR) in the juxtaposed muscle ﬁber. This pre-synaptic ACh
release induces a global change in muscle calcium levels leading
to muscle contractions. To examine the structure of the NMJ,
antibodies were used to label the axon (neuroﬁlament NF-M), pre-
synaptic vesicles (SV2) and post-synaptic AChR clusters (α-bun-
garotoxin, α-BTX). Soleus muscles from E18.5 littermate controls
showed co-localization of axons, synaptic vesicles and AChR
clusters (Fig. 4A–D). Pex10CY/CY soleus muscle showed decreased
co-localization of axons with AChR clusters (Fig. 4E–H). Moreover,
several axons with adjacent AChR clusters lacked synaptic vesicle
labeling (quantiﬁcation of results in Fig. 4I and J). This data
suggests structural deﬁcits in Pex10CY/CY hindlimb synapses.
Together, the identiﬁed defects in synaptic machinery of the
hindlimb muscle and in axon integrity of the sciatic nerve may
point to an embryonic neurodegenerative-like disorder under-
lining the progressive loss of movement in Pex10CY/CY embryos.
Defects of axons, Schwann cells and synapses in Pex10CY/CY
diaphragm muscles
In patients with neurodegenerative disorders, such as amyo-
trophic lateral sclerosis (ALS), immobility is progressive, ﬁrst
affecting the legs, followed by arms and ﬁnally the axial muscu-
lature, which affects respiration. The lack of respiration in Pex10CY/
CY mutant mice at birth led us to examine innervation of the
diaphragm muscle during two stages of fetal development.
At E15.5, Pex10CY/CY and littermate control diaphragms showed
similar AChR cluster patterning (Fig. 5A–C; α-BTX). However,
many phrenic axons in E15.5 Pex10CY/CY mutant embryos extended
abnormally beyond the AChR clusters (Fig. 5A–C, F; axons labeled
by NF-M and SV2). E18.5 Pex10CY/CY embryos with modest fore-
Fig. 4. Pex10CY/CY soleus muscle exhibits NMJ defects. (A)–(H) E18.5 soleus muscle from wildtype (A)–(D) and Pex10CY/CY (E)–(H) littermates labeled with NF-M (axons, red),
SV2 (pre-synaptic vesicles, green) and α-BTX (post-synaptic AChR clusters, blue). (A)–(D) Stereotypical pattern of innervation in wildtype soleus muscle with co-localization
of pre- and post-synaptic apparatus. (E)–(H) In Pex10CY/CY mutants there is not a strong correspondence between NF-M, SV2, and α-BTX labeling. (I) Quantiﬁcation of NF-M
positive axons that are opposed to α-BTXþ AChR clusters. (J) Quantiﬁcation of SV2 positive vesicles adjacent to α-BTXþ AChR clusters. White arrows in E–H indicate α-BTXþ
AChR clusters that lack SV2þ and NF-Mþ co-labeling. Scale bar¼50 μm. Asterisks indicate a signiﬁcant difference (po0.005; t-test).
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limb movement showed highly signiﬁcant extension of the axons
beyond the relatively normally distributed AChR clusters, although
within the central region of the diaphragm the axons were directly
juxtaposed to the AChR clusters (Fig. 5E and F). This data suggests
that Pex10CY/CY axons do not halt axon extension after synapse
formation.
The mechanisms involved in halting axon extension in muscle
during synaptogenesis are not well understood, but likely require
signals intrinsic to the developing axons as well as extrinsic
signals derived from Schwann cells and the target muscle. During
peripheral nerve regeneration, Schwann cells are crucial in aiding
the navigation of axons to synaptic sites in muscle (Kang et al.,
2003; Son and Thompson, 1995). During embryonic development,
immature Schwann cells and terminal Schwann cells might have a
similar role in the early formation and maintenance of the NMJ.
The reduced labeling with the Schwann cell marker and aberrant
Schwann cell morphology by EM of E18.5 Pex10CY/CY sciatic nerve
led us to evaluate Schwann cells in the diaphragm muscle using an
Fig. 5. Pex10CY/CY diaphragms display defects in axon extension and Schwann cell placement. (A), (B), (D), (E) E15.5 (A) and (B) and E18.5 (D) and (E) wildtype and Pex10CY/CY
diaphragms labeled with NF-M/SV2 (axons and pre-synaptic sites) and α-BTX (post-synaptic AChR clusters). (C) Quantiﬁcation as a percentage of the region of the diaphragm
with AChR clusters in E15.5 and E18.5 wildtype and Pex10CY/CY diaphragms. (F) Quantiﬁcation of axon extension beyond the AChR clusters in E15.5 and E18.5 Pex10CY/CY
diaphragms. (G) and (H) E18.5 wildtype (G) and Pex10CY/CY (H) diaphragms labeled with NF-M (axons), α-BTX (post-synaptic AChR clusters) and SOX10 (Schwann cell nuclei,
green). (I) Quantiﬁcation of percentage of nerves with SOX10 positive nuclei at the terminal end of the nerve. (J) Quantiﬁcation of SOX10 positive nuclei along the length of
the nerve. (K) Quantiﬁcation of SOX10 positive nuclei adjacent to AChR clusters. (A), (B), (D), (E) Scale bar¼200 μm. (G)–(H) Scale bar¼50 μm. Asterisks indicate a signiﬁcant
difference (po0.005; t-test).
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antibody to SOX10 which localizes to Schwann cell nuclei along
axons and at synapses (Fig. 5G and H: green label). E18.5 Pex10CY/CY
diaphragm had a signiﬁcant decrease in SOX10 positive cells
located terminally on axons (Fig. 5G–I; control: 89.976.8% of
nerves with a SOX10 positive terminal cell; n¼4 compared to
Pex10CY/CY: 35.376.1; n¼4) and adjacent to axons (Fig. 5J; control:
0.06270.012 SOX10 positive nuclei/μm of nerve; n¼4 compared
to Pex10CY/CY: 0.02670.011 μm; n¼4). The percent of SOX10 posi-
tive cells juxtaposed to AChR clusters was also reduced compared
to littermate control embryos (Fig. 5G–K; control: 92.473.2; n¼4
compared to Pex10CY/CY: 56.978.8; n¼4). These data suggest that
Pex10CY/CY diaphragms have defects in proper Schwann cell place-
ment at neuromuscular junctions.
Together, the differences observed between Pex10CY/CY and
control diaphragms in the phrenic nerve, Schwann cells and
synapses may result in altered synaptic transmission at the
neuromuscular junction. The NMJ releases small packets of neuro-
transmitter spontaneously, termed spontaneous release, or action
potential transmitter release, termed evoked release. Spontaneous
neuromuscular synaptic activity, as measured by miniature end-
plate potential (MEPP) frequency (events per minute) in muscle,
was unchanged in E18.5 Pex10CY/CY diaphragm (0.8570.25, n¼18
cells, n¼3 embryos, 70 total events in 82 min) compared with
wildtype diaphragm (0.7270.31, n¼16 cells, n¼3 embryos, 67
total events in 93 min; p40.05; Fig. 6A–C). Examinations of the
amplitudes of MEPP showed no variability between Pex10CY/CY
muscles (1.9970.15 mV, n¼18 cells and 3 embryos) compared
with wildtype (2.0170.14 mV, n¼16 cells and 3 embryos; p4
0.05; Fig. 6A, B and D).
To examine motor axon functional physiology, action potential
evoked endplate potentials (EPP) were induced by stimulation of
the phrenic nerve. EPP amplitudes were signiﬁcantly decreased in
Pex10CY/CY muscles (17.2973.29 mV, n¼16 cells and 3 embryos)
compared to control (30.1777.16 mV, n¼14 cells and 3 embryos;
Fig. 6E–G). EPP stimulation induced muscle contractions in control
and Pex10CY/CY muscles (arrow in Fig. 6E and G). These data suggest
that synaptic transmission at the diaphragm is present, although
diminished, in E18.5 Pex10CY/CY diaphragms.
Discussion
Zellweger syndrome, NALD, cerebellar ataxia, spinal ataxia, and
progressive ataxia are diagnoses in patients with mutations in
PEX10 (Steinberg et al., 2004; Warren et al., 2000). Despite the fact
that neurological deﬁcits can be observed at birth in some PBD
patients including those with PEX10 mutations, the embryological
basis of the disease is unclear. Here, we present a mouse model of
PBD that illuminates defects in the spinal locomotion circuit prior
to birth. First, we identiﬁed a mutation in Pex10 that causes
neonatal mortality and progressive loss of movement during
embryogenesis, prior to the onset of cerebellar inputs that do
not develop until after birth. Second, Pex10CY/CY embryos acquire
pathological and biochemical hallmarks similar to patients with
PBD. Third, white matter, sciatic nerves, and motor axons inner-
vating hindlimb muscles in Pex10CY/CY embryos display character-
istic signs of defects in axon integrity. Fourth, Schwann Cells are
decreased in number and misplaced along axons and synapses of
muscles in Pex10CY/CY embryos. Fifth, phrenic nerves of Pex10CY/CY
embryos extend their axons beyond AChR clusters, and display
decreased action potential release of transmitter onto the muscle.
During embryogenesis, nutrients are provided across the pla-
centa to the embryos. However, poly-unsaturated fatty acids, such
as plasmalogens, are locally synthesized by the embryo (Janssen
et al., 2000). Our biochemical analyses of Pex10CY/CY embryos show
that PEX10 is required for embryonic plasmalogen synthesis in
mice. The ﬁnding of aberrant biomarkers in the mutant mouse
embryos suggests the possibility of prenatal screening for perox-
isomal dysfunction. Pex2 and Pex5 deﬁcient neonates also show
decreased synthesis of plasmalogens and increased plasma VLCFA
(Baes et al., 1997; Faust and Hatten, 1997) and PEX2 and PEX5
function with PEX10 for cargo import and plasmalogen synthesis
(Oeljeklaus et al., 2012; Williams et al., 2008, 2012). Both Pex2 and
Pex5 deﬁcient mice die shortly after birth from what was con-
sidered a feeding defect and not a respiratory defect (Baes et al.,
1997; Faust and Hatten, 1997). On a congenic 129svJ background,
the same background examined in our study, Pex2 deﬁcient mice
showed a 20% increase in embryonic mortality (Faust and Hatten,
1997). Tissue-speciﬁc knock-out of Pex5 in the liver allowed
Fig. 6. Pex10CY/CY diaphragm muscle displays decreased evoked transmitter release.
Sharp electrode recordings of E18.5 wildtype and Pex10CY/CY diaphragms in Ringer’s
solution. (A) and (B) Representative spontaneous EPP (MEPP) from E18.5 wildtype
and Pex10CY/CY diaphragms. (C) and (D) Quantiﬁcation of MEPP frequency and
amplitude. (E) and (F) Representative evoked EPP from E18.5 wildtype and Pex10CY/
CY diaphragms (Note; arrows highlight the muscle contraction after the EPP).
(G) Quantiﬁcation of EPP amplitude. Scale bars adjacent to traces in B and F.
Asterisk in G indicates a signiﬁcant difference (p¼0.001; t-test).
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survival but resulted in persistent cerebellar atrophy, whereas
conditional knock-out of Pex5 in neurons and Schwann cells also
allowed survival but resulted in cortical migration and demyeli-
nation abnormalities as well as increased neuroinﬂammatory
response (Bottelbergs et al., 2012; Hulshagen et al., 2008; Krysko
et al., 2007). The differences in mortality of Pex10CY/CY mutants and
other PEX deﬁcient mouse models might be due to differences in
genetic background, the genetic allele, or partial compensation of
function. In the future it will be of interest to determine whether
decreased axon integrity is a common feature of peroxisomal
dysfunction. In patients with PBD, mutations in PEX genes are
likely to induce protein dysfunction and less likely to eliminate
protein expression (Steinberg et al., 2006; Wanders and
Waterham, 2005, 2006). Future studies in animal models exploit-
ing the use of mixed and congenic backgrounds, conditional
knock-outs, and hypomorphic alleles will help to elucidate the
role of peroxisomal biogenesis factors in embryonic and neonatal
neurodevelopment.
The Pex10 mutant identiﬁed here provides a model to evaluate
PNS pathology that leads to progressive locomotor defects.
Schwann cells are the principle myelinating glia cells of the PNS.
Schwann cells target and wrap the motor axon while the terminal
Schwann cells encapsulate the NMJ for proper locomotion
(Pincon-Raymond et al., 1987). PEX7 has been implicated in
Schwann cell myelination and remyelination and plasmalogen
synthesis in postnatal and adult mice (da Silva et al., 2014). PEX7
requires E3 ligase activity of PEX10 for cargo import (Titorenko
and Rachubinski, 2001a, 2001b). Our data demonstrate defects in
Schwann cell form and function during embryogenesis and prior
to axonal myelination (Martin and Webster, 1973; Webster et al.,
1973). Early during murine embryogenesis (E14.5–15.5), Schwann
cells encapsulate bundles of motor axons and form a terminal cap
at the synapse, which helps stabilize the synapse (Jessen and
Mirsky, 2005; Reddy et al., 2003). The early events that lead to
the formation and stability of the NMJ at embryonic stages are
essential for the function of the NMJ in adult muscle. The
respiratory defects of the Pex10CY/CY mice at birth and aberrant
Schwann cell numbers suggest that communication between the
spinal cord and diaphragm is impaired. Moreover, the abnormal
sprouting of the phrenic nerve and decreased EPP amplitude in the
E18.5 diaphragm suggests failure to establish or maintain stable
synaptic connections. Our model suggests that progressive motor
loss in Pex10CY/CY mice might be due to failure to stabilize the
synapse during fetal development, at least in part due to abnormal
Schwann cell function, followed by progressive loss of axon
integrity.
In summary, the Pex10 mutant mouse presents a novel and
valuable model for examination of embryonic deﬁcits due to PBD.
Our data illustrates the importance of PEX10 during the early
formation of the spinal locomotion circuit, axonal integrity and
synapse formation. PBDs due to Pex mutations affect peroxisome
function (Braverman et al., 2013; Steinberg et al., 2006), similar to
what is observed in the Pex10CY/CY model. Therefore, the pathology
described in the PNS of Pex10CY/CY mice may be common for all
PBD that display hypotonia and defects in locomotion at birth.
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